Scholarlink

Background <p>The role of aspirin for primary prevention remains debated, especially around discontinuation in Thailand. Western studies suggest higher cardiovascular risk after cessation, but Southeast Asian evidence is limited and may differ.</p> Objective <p>To determine the association between aspirin discontinuation and cardiovascular disease (CVD) risk among Thai adults using low-dose aspirin for primary prevention, and to explore patient and clinician perspectives underlying discontinuation.</p> Methods <p>We conducted a descriptive study at Phramongkutklao Hospital (2014–2024). The index date was aspirin initiation; follow-up accrued from the next day until first outcome, death, last encounter, or 31 Dec 2024. Aspirin exposure was modeled time-varyingly: person-time counted as continued until protocol-defined discontinuation (≥ 90-day gap after the expected end of supply) and as discontinued thereafter. Adults prescribed low-dose aspirin (75–162&#xa0;mg/day) for primary prevention were included (<i>n</i> = 408). The primary outcome was a composite of acute coronary syndrome, ischemic stroke, or cardiovascular death. Time-to-event analyses used Kaplan–Meier and Cox models with time-updated exposure. Interviews with 24 patients and 12 clinicians were conducted to explore major biases.</p> Results <p>Discontinuation was associated with higher CVD risk (adjusted HR 1.72, 95% CI 1.06–2.80; <i>p</i> = 0.028). Risk was greater among patients with diabetes (adjusted HR 2.12; <i>p</i> = 0.047) and among short-term users (&lt; 5 years; adjusted HR 2.01; <i>p</i> = 0.049). Event-free survival was lower after discontinuation (log-rank <i>p</i> = 0.003). Qualitative themes explained why discontinuation occurs: bleeding-risk salience, temporary peri-procedural holds becoming permanent, pill burden, and doctor-led decisions with a need for simple written rules.</p> Conclusion <p>Stopping aspirin was linked to increased cardiovascular risk—particularly among short-term users and patients with diabetes, with similar but non-significant trends observed in those with hypertension or dyslipidemia. Qualitative insights highlight pragmatic solutions—clear restart plans, aligned clinician messaging, and concise risk-framing—to support individualized decisions in Thai outpatient care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Discontinuation of aspirin for primary prevention and increased risks of cardiovascular disease in a descriptive study from Thailand

  • 期刊论文

  • 发表日期：

    2026年1月14日

查看全文
  • Kraisit Phakwiwat,
  • Korawee Matesareyapong,
  • Thanapat Limpaarayakul,
  • Kasidid Lawongsa

摘要

Background

The role of aspirin for primary prevention remains debated, especially around discontinuation in Thailand. Western studies suggest higher cardiovascular risk after cessation, but Southeast Asian evidence is limited and may differ.

Objective

To determine the association between aspirin discontinuation and cardiovascular disease (CVD) risk among Thai adults using low-dose aspirin for primary prevention, and to explore patient and clinician perspectives underlying discontinuation.

Methods

We conducted a descriptive study at Phramongkutklao Hospital (2014–2024). The index date was aspirin initiation; follow-up accrued from the next day until first outcome, death, last encounter, or 31 Dec 2024. Aspirin exposure was modeled time-varyingly: person-time counted as continued until protocol-defined discontinuation (≥ 90-day gap after the expected end of supply) and as discontinued thereafter. Adults prescribed low-dose aspirin (75–162 mg/day) for primary prevention were included (n = 408). The primary outcome was a composite of acute coronary syndrome, ischemic stroke, or cardiovascular death. Time-to-event analyses used Kaplan–Meier and Cox models with time-updated exposure. Interviews with 24 patients and 12 clinicians were conducted to explore major biases.

Results

Discontinuation was associated with higher CVD risk (adjusted HR 1.72, 95% CI 1.06–2.80; p = 0.028). Risk was greater among patients with diabetes (adjusted HR 2.12; p = 0.047) and among short-term users (< 5 years; adjusted HR 2.01; p = 0.049). Event-free survival was lower after discontinuation (log-rank p = 0.003). Qualitative themes explained why discontinuation occurs: bleeding-risk salience, temporary peri-procedural holds becoming permanent, pill burden, and doctor-led decisions with a need for simple written rules.

Conclusion

Stopping aspirin was linked to increased cardiovascular risk—particularly among short-term users and patients with diabetes, with similar but non-significant trends observed in those with hypertension or dyslipidemia. Qualitative insights highlight pragmatic solutions—clear restart plans, aligned clinician messaging, and concise risk-framing—to support individualized decisions in Thai outpatient care.